Evidence map›Paper›PMID 31464835›Full record

ArticleJournal of infusion nursing : the official publication of the Infusion Nurses Society

Safety Profile of HTX-019 Administered as an Intravenous Infusion in Patients With Cancer: A Retrospective Analysis.

George Calcanes, Jeffrey L Vacirca

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of infusion nursing : the official publication of the Infusion Nurses Society. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

George CalcanesNew York Cancer & Blood Specialists, East Setauket, New York (Mr Calcanes and Dr Vacirca). George Calcanes, BS, RN, is chief clinical officer at New York Cancer & Blood Specialists, where he manages an extensive oncology practice with infusion suites for outpatient chemotherapy. He institutes new chemotherapy regimens, clinics, and services for a large patient population, coordinating between clinical staff and pharmaceutical companies for optimal patient care. Jeffrey L. Vacirca, MD, FACP, is chief executive officer, managing partner, and director of clinical research at New York Cancer & Blood Specialists. He is also medical director for the International Oncology Network in Frisco, Texas; president of Community Oncology Alliance; and president of the National Translational Research Group in East Setauket, NY. His specialties include breast, prostate, and complicated cancers.
Jeffrey L Vacirca

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

HTX-019 is a neurokinin 1 receptor antagonist approved for prevention of acute and delayed chemotherapy-induced nausea and vomiting in patients with cancer receiving moderately and highly emetogenic chemotherapy. When administered as a 30-minute intravenous (IV) infusion, HTX-019 has displayed a tolerable and favorable safety profile in healthy subjects. This is the first study to evaluate the safety profile of multiple HTX-019 infusions in patients with cancer. This retrospective analysis shows that HTX-019 administered via IV infusion has a favorable safety profile in patients with cancer, and no new treatment-emergent adverse events were identified.

Indexed as

Infusions, IntravenousAgedAntiemeticsAntineoplastic Combined Chemotherapy ProtocolsAprepitantFemaleHumansMaleNauseaNeoplasmsNeurokinin-1 Receptor AntagonistsRetrospective StudiesVomitingAntiemeticsAprepitantNeurokinin-1 Receptor Antagonists

Identifiers

PMID31464835
PMCPMC7328855

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.